Načítá se...
Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?
The activation of the PI3K/AKT/mTOR pathway is a main driver of cell growth, proliferation, survival, and chemoresistance of cancer cells, and, for this reason, represents an attractive target for developing targeted anti-cancer drugs. There are plenty of preclinical data sustaining the anti-tumor a...
Uloženo v:
| Vydáno v: | Int J Mol Sci |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
MDPI
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7037719/ https://ncbi.nlm.nih.gov/pubmed/32033478 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21031060 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|